Pharvaris NV
Research Pharvaris NV (PHVS) on Bullrun: market cap USD 2.17B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPHVS
- ExchangeNASDAQ
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.17B
- Financial periodQ2 2026
- RevenueEUR 0
- Net income-EUR 47.84M
- Free cash flow-EUR 37.83M
Valuation Snapshot
latest market cap is USD 2.17B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 175.70M | -EUR 137.24M | n/a | -2.97 | EUR 291.68M | EUR 776.80K | EUR 271.27M |
| FY2024 | EUR 0 | -EUR 134.22M | -EUR 120.67M | n/a | -2.48 | EUR 280.73M | EUR 861.47K | EUR 267.76M |
| FY2023 | EUR 0 | -EUR 100.88M | -EUR 93.14M | n/a | -2.63 | EUR 391.23M | EUR 238.91K | EUR 384.05M |
| FY2022 | EUR 0 | -EUR 76.33M | -EUR 67.29M | n/a | -2.27 | EUR 161.84M | EUR 436.82K | EUR 149.26M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 2.17B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.81B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.04B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.46B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 380.11M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 477.06M | n/a | n/a | n/a |
About Pharvaris NV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Related stock research
Other Healthcare stocks
AC Immune SA (ACIU)
Addex Therapeutics Ltd (ADXN)
Bachem Holding AG (BANB)
BB Biotech AG (BION.SW)
Bioversys AG (BIOV)
Basilea Pharmaceutica AG (BSLN)
CRISPR Therapeutics AG (CRSP)
Idorsia Ltd (IDIA)
MoonLake Immunotherapeutics - Class A (MLTX)
MindMaze Therapeutics Holding SA (MMTX.SW)
Molecular Partners AG (MOLN)
NLS Pharmaceutics Ltd (NCEL)
Frequently asked questions
What is Pharvaris NV's market cap?
Pharvaris NV's market capitalization is USD 2.17B.
What does Pharvaris NV do?
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.